122 related articles for article (PubMed ID: 35857974)
1. ERG and OCT abnormalities in retinoblastoma after melphalan intravitreous injection.
Albuquerque ML; Moreto R; Bergamo M; Corrêa ZM; Jorge R
Arq Bras Oftalmol; 2022; 87(1):0037. PubMed ID: 35857974
[TBL] [Abstract][Full Text] [Related]
2. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.
Francis JH; Schaiquevich P; Buitrago E; Del Sole MJ; Zapata G; Croxatto JO; Marr BP; Brodie SE; Berra A; Chantada GL; Abramson DH
Ophthalmology; 2014 Sep; 121(9):1810-7. PubMed ID: 24819859
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal melphalan hydrochloride vs propylene glycol-free melphalan for retinoblastoma vitreous seeds: Efficacy, toxicity and stability in rabbits models and patients.
Bogan CM; Pierce JM; Doss SD; Tao YK; Chen SC; Boyd KL; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
Exp Eye Res; 2021 Mar; 204():108439. PubMed ID: 33444583
[TBL] [Abstract][Full Text] [Related]
4. Diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report.
Chao A; Kao LY; Liu L; Wang NK
BMC Ophthalmol; 2016 Mar; 16():27. PubMed ID: 26975871
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.
Kaczmarek JV; Bogan CM; Pierce JM; Tao YK; Chen SC; Liu Q; Liu X; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Friedman DL; Richmond A; Daniels AB
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):8. PubMed ID: 34757417
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience.
Francis JH; Brodie SE; Marr B; Zabor EC; Mondesire-Crump I; Abramson DH
Ophthalmology; 2017 Apr; 124(4):488-495. PubMed ID: 28089679
[TBL] [Abstract][Full Text] [Related]
7. Changes in Retinal Thickness on OCT from Intravitreal Melphalan.
Narala R; Kim JW; Lang P; Le BHA; Hendargo HC; Branco D; Berry JL
Ophthalmol Retina; 2019 Mar; 3(3):288-289. PubMed ID: 31014710
[No Abstract] [Full Text] [Related]
8. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma.
Brodie SE; Munier FL; Francis JH; Marr B; Gobin YP; Abramson DH
Doc Ophthalmol; 2013 Feb; 126(1):79-84. PubMed ID: 23143758
[TBL] [Abstract][Full Text] [Related]
9. Is intravitreal topotecan toxic to retinal function?
Nadelmann J; Francis JH; Brodie SE; Muca E; Abramson DH
Br J Ophthalmol; 2021 Jul; 105(7):1016-1018. PubMed ID: 32665221
[TBL] [Abstract][Full Text] [Related]
10. Toxicity to intravitreal melphalan in a patient with retinoblastoma.
Solaz-Ruiz MG; Pérez LA; Cauto-Picazo C; Barranco-González H; Pascual-Camps I; España-Gregori E
Rom J Ophthalmol; 2023; 67(3):305-308. PubMed ID: 37876503
[No Abstract] [Full Text] [Related]
11. TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µg.
Liao A; Hsieh T; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
Retina; 2021 Jan; 41(1):208-212. PubMed ID: 32106160
[TBL] [Abstract][Full Text] [Related]
12. Cystoid macular edema following intravitreal chemotherapy treatment for retinoblastoma.
Panthagani J; Montecinos P; López JP; Parulekar M
Pediatr Blood Cancer; 2020 Sep; 67(9):e28348. PubMed ID: 32634267
[No Abstract] [Full Text] [Related]
13. Anterior Ocular Toxicity of Intravitreous Melphalan for Retinoblastoma.
Francis JH; Marr BP; Brodie SE; Abramson DH
JAMA Ophthalmol; 2015 Dec; 133(12):1459-63. PubMed ID: 26378741
[TBL] [Abstract][Full Text] [Related]
14. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.
Xue K; Ren H; Meng F; Zhang R; Qian J
BMC Ophthalmol; 2019 Feb; 19(1):61. PubMed ID: 30808420
[TBL] [Abstract][Full Text] [Related]
15. INTRAVITREAL MELPHALAN AS SALVAGE THERAPY FOR REFRACTORY RETINAL AND SUBRETINAL RETINOBLASTOMA.
Francis JH; Marr BP; Brodie SE; Gobin P; Dunkel IJ; Abramson DH
Retin Cases Brief Rep; 2016; 10(4):357-60. PubMed ID: 26630243
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma.
Hsieh T; Liao A; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
PLoS One; 2020; 15(7):e0235016. PubMed ID: 32609726
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
[TBL] [Abstract][Full Text] [Related]
18. INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture.
Shields CL; Douglass AM; Beggache M; Say EA; Shields JA
Retina; 2016 Jun; 36(6):1184-90. PubMed ID: 26630319
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.
Ghassemi F; Shields CL
Arch Ophthalmol; 2012 Oct; 130(10):1268-71. PubMed ID: 23044940
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study.
Bogan CM; Kaczmarek JV; Pierce JM; Chen SC; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Nadelmann JB; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
Br J Ophthalmol; 2022 Feb; 106(2):288-296. PubMed ID: 33972235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
